Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral erythromycin for feeding intolerance in premature infants
IRCT20120614010026N10Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of erythromycin in feeding intolerance (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Time to reach 75 cc/kg/day feeding volume, Time to reach 110 cc/kg/day feeding volume and 1 more. Started Mar 2016; status: completed.
02
Drugs
erythromycin
03
Conditions
feeding intolerance
Beyond the preview
Go deeper on IRCT20120614010026N10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120614010026N10.